Literature DB >> 21275058

Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

T Eric Ballard1, Xia Wang, Igor Olekhnovich, Taylor Koerner, Craig Seymour, Joseph Salamoun, Michelle Warthan, Paul S Hoffman, Timothy L Macdonald.   

Abstract

A library composed of nitazoxanide-based analogues was synthesized and assayed for increased antibacterial efficacy against the pyruvate-ferredoxin oxidoreductase (PFOR) using microorganisms Helicobacter pylori, Campylobacter jejuni and Clostridium difficile. Derivatives were found to recapitulate and improve activity against these organisms and select analogues were tested for their ability to disrupt the PFOR enzyme directly. The library was also screened for activity against staphylococci and resulted in the identification of analogues capable of inhibiting both staphylococci and all PFOR organisms at low micromolar minimum inhibitory concentrations with low toxicity to human foreskin cells.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21275058      PMCID: PMC3089805          DOI: 10.1002/cmdc.201000475

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  36 in total

Review 1.  Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer.

Authors:  L Fuccio; R M Zagari; M E Minardi; F Bazzoli
Journal:  Aliment Pharmacol Ther       Date:  2007-01-15       Impact factor: 8.171

2.  A new ferredoxin-dependent carbon reduction cycle in a photosynthetic bacterium.

Authors:  M C Evans; B B Buchanan; D I Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  1966-04       Impact factor: 11.205

Review 3.  Staphylococcus epidermidis infections.

Authors:  Cuong Vuong; Michael Otto
Journal:  Microbes Infect       Date:  2002-04       Impact factor: 2.700

4.  Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae.

Authors:  Eliah R Shamir; Michelle Warthan; Sareena P Brown; James P Nataro; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

5.  Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole.

Authors:  F Mégraud; A Occhialini; J F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

6.  Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species.

Authors:  Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.

Authors:  Jean-François Rossignol; Asem Elfert; Yehia El-Gohary; Emmet B Keeffe
Journal:  Gastroenterology       Date:  2008-11-19       Impact factor: 22.682

8.  Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru.

Authors:  Jave Ortiz Juan; Nicholas Lopez Chegne; Gilles Gargala; Loic Favennec
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Mar-Apr       Impact factor: 2.184

9.  Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance.

Authors:  Luiz Pedro S de Carvalho; Gang Lin; Xiuju Jiang; Carl Nathan
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

10.  Molecular and phylogenetic characterization of pyruvate and 2-ketoisovalerate ferredoxin oxidoreductases from Pyrococcus furiosus and pyruvate ferredoxin oxidoreductase from Thermotoga maritima.

Authors:  A Kletzin; M W Adams
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

View more
  11 in total

1.  The small molecule nitazoxanide selectively disrupts BAM-mediated folding of the outer membrane usher protein.

Authors:  John J Psonis; Peter Chahales; Nadine S Henderson; Nathan W Rigel; Paul S Hoffman; David G Thanassi
Journal:  J Biol Chem       Date:  2019-08-07       Impact factor: 5.157

2.  Synthesis and Antimicrobial Evaluation of Amixicile-Based Inhibitors of the Pyruvate-Ferredoxin Oxidoreductases of Anaerobic Bacteria and Epsilonproteobacteria.

Authors:  Andrew J Kennedy; Alexandra M Bruce; Catherine Gineste; T Eric Ballard; Igor N Olekhnovich; Timothy L Macdonald; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

3.  Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori.

Authors:  Paul S Hoffman; Alexandra M Bruce; Igor Olekhnovich; Cirle A Warren; Stacey L Burgess; Raquel Hontecillas; Monica Viladomiu; Josep Bassaganya-Riera; Richard L Guerrant; Timothy L Macdonald
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

4.  Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.

Authors:  Cirle A Warren; Edward van Opstal; T Eric Ballard; Andrew Kennedy; Xia Wang; Mary Riggins; Igor Olekhnovich; Michelle Warthan; Glynis L Kolling; Richard L Guerrant; Timothy L Macdonald; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

5.  Synthesis, in vitro bioassays, and computational study of heteroaryl nitazoxanide analogs.

Authors:  Tasmia Ahmed; S M Abdur Rahman; Muhammad Asaduzzaman; Abul Bashar Mir Md Khademul Islam; A K Azad Chowdhury
Journal:  Pharmacol Res Perspect       Date:  2021-05

6.  N-(5-Nitro-1,3-thia-zol-2-yl)-4-(tri-fluoro-meth-yl)benzamide.

Authors:  Xi-Wang Liu; Han Zhang; Ya-Jun Yang; Jian-Yong Li; Ji-Yu Zhang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-05-22

7.  N-(5-Chloro-1,3-thia-zol-2-yl)-2,4-difluoro-benzamide.

Authors:  Xi-Wang Liu; Jian-Yong Li; Han Zhang; Ya-Jun Yang; Ji-Yu Zhang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-05-23

8.  Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis.

Authors:  Karen K Y Lam; Xingji Zheng; Roberto Forestieri; Aruna D Balgi; Matt Nodwell; Sarah Vollett; Hilary J Anderson; Raymond J Andersen; Yossef Av-Gay; Michel Roberge
Journal:  PLoS Pathog       Date:  2012-05-10       Impact factor: 6.823

Review 9.  Clostridium difficile drug pipeline: challenges in discovery and development of new agents.

Authors:  Angie M Jarrad; Tomislav Karoli; Mark A T Blaskovich; Dena Lyras; Matthew A Cooper
Journal:  J Med Chem       Date:  2015-03-30       Impact factor: 7.446

Review 10.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.